{
    "organizations": [],
    "uuid": "713fbf1ef8b440b2ae7dd79ca84c9ab9a3891ffb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-agios-reports-qtrly-loss-per-share/brief-agios-reports-qtrly-loss-per-share-1-81-idUSASB0C5MY",
    "ord_in_thread": 0,
    "title": "BRIEF-Agios Reports Qtrly Loss Per Share $1.81",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Agios Pharmaceuticals Inc:\n* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* QTRLY LOSS PER SHARE $1.81 * QTRLY TOTAL REVENUE $9.8 MILLION VERSUS $22.6 MILLION * Q4 EARNINGS PER SHARE VIEW $-1.66 -- THOMSON REUTERS I/B/E/S\n* AGIOS PHARMACEUTICALS - SEES CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 ENABLING CO TO FUND EXPENSES, CAPEX REQUIREMENTS THROUGH AT LEAST END OF 2020 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T20:06:00.000+02:00",
    "crawled": "2018-02-15T20:38:09.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "agio",
        "pharmaceutical",
        "inc",
        "agio",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "qtrly",
        "loss",
        "per",
        "share",
        "qtrly",
        "total",
        "revenue",
        "million",
        "versus",
        "million",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "agio",
        "pharmaceutical",
        "see",
        "cash",
        "cash",
        "equivalent",
        "dec",
        "enabling",
        "co",
        "fund",
        "expense",
        "capex",
        "requirement",
        "least",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}